United States: Federal Court Rejects HHS Interpretation Of 340B Program's Orphan Drug Rule

On October 14, 2015, the United States District Court for the District of Columbia (the Court) issued a decision in Pharmaceutical Research and Manufacturers of America v. United States Department of Health and Human Services, et al. In this case, Pharmaceutical Research and Manufacturers of America (PhRMA) challenged interpretive guidance issued by the Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Resources, pertaining to the 340B Drug Pricing Program's (340B Program) so-called "orphan drug exclusion." In sum, the Court found HRSA's interpretive guidance to be contrary to the plain language of the 340B statute.

The Court's opinion follows an earlier decision from 2014 ( see here), in which the Court held that HRSA did not have the requisite statutory authority to issue formal rules on the subject of the orphan drug exclusion.

The 340B Program allows certain providers (Covered Entities) to purchase "covered outpatient drugs" from drug manufacturers at discounted prices. The Affordable Care Act (ACA) extended eligibility to participate in the 340B Program to certain additional types of hospitals (including critical access hospitals, sole community hospitals, rural referral centers and freestanding cancer hospitals). The ACA also added a provision to the 340B statute (codified at 42 U.S.C. § 256b(e)), applicable only to those newly eligible hospitals, that specifically excluded from the definition of "covered outpatient drugs" certain drugs designated by the U.S. Food and Drug Administration (FDA) for a rare disease or condition (orphan drugs). As a result of this "orphan drug exclusion," those newly eligible hospitals are unable to purchase orphan drugs at the 340B price.

As noted briefly above, HRSA previously sought to issue a formal rule interpreting the orphan drug exclusion. HRSA's formal rule provided that affected hospitals that track drugs by indication could purchase orphan drugs at the 340B price if such drugs were to be used for non-orphan indications. If the drugs were to be used for orphan indications, or if an affected hospital did not track drugs by indication, then orphan drugs could not be purchased at the 340B price.  Thus, those affected hospitals were able to purchase orphan drugs at the 340B price where such orphan drugs were to be used for non-orphan indications. In the 2014 opinion referenced above, the Court held that HRSA did not have the requisite statutory authority to issue a formal rule interpreting the orphan drug exclusion. Notably, in that 2014 decision, the Court did not give an opinion on the validity of HRSA's interpretation of the orphan drug exclusion.

Following the 2014 decision, HRSA reissued the content of the formal rule — specifically, that ACA-eligible hospitals could purchase orphan drugs at 340B prices if the drugs were to be used for non-orphan indications — as interpretive guidance (Orphan Drug Guidance). PhRMA again brought suit against HRSA, this time challenging the substance of the Orphan Drug Guidance.

At the outset of its decision, the Court acknowledged HRSA's authority to generally interpret the 340B statute, and to make public its interpretations through guidance. Prior to ruling on the substance of the Orphan Drug Guidance, the Court made a threshold determination that the guidance was a "final agency action" and therefore was subject to judicial review. To arrive at this conclusion, the Court found that (i) the Orphan Drug Guidance was clearly the "consummation" of HRSA's decision-making process, and was not tentative or interlocutory in nature; and (ii) that the Orphan Drug Guidance would create legal rights and consequences for drug manufacturers. In finding that the Orphan Drug Guidance would in fact create legal rights and consequences, the Court rejected HRSA's argument that since HRSA had not yet enforced the requirements of the Orphan Drug Guidance against any drug manufacturer, that no legal rights had been created by the guidance. The Court acknowledged that so-called "pre-enforcement" challenges to agency review were legally acceptable in certain instances, and found that the Orphan Drug Guidance was subject to challenge despite the fact that HRSA had not yet undertaken any enforcement activities for noncompliance with the Orphan Drug Guidance.

After determining that the Orphan Drug Guidance was a "final agency action" subject to judicial review, the Court sought to determine whether the substance of the guidance was a valid interpretation of the 340B statute. After weighing the appropriate level of deference to be given to HRSA's interpretation, the Court concluded that HRSA's orphan drug guidance was "contrary to the plain language of section 340B(e)." In reaching this conclusion, the Court looked to the language of the statute, which states the orphan drug exclusion applies to those drugs that are "designated... for a rare disease or condition." Although acknowledging that HRSA's interpretation "might appear plausible at first glance, and when confined solely to section 340B(e)," the Court examined the interpretation in the context of related provisions of federal law. Thereafter, the Court pointed out that in related areas of federal law, language is used to differentiate specifically the use of a drug and such drug's designation as an orphan drug. Since Section 340B(e) does not include such differential language, the Court concluded that the statute would not permit HRSA's interpretation that drugs which have orphan designations but are not used for the rare disease or condition for which the designation was made, could be purchased at the 340B price.

In light of the Court's decision to invalidate HRSA's Orphan Drug Guidance, it is possible that HRSA will be vulnerable to legal challenges to its recently issued proposed omnibus guidance related to the 340B Program. Such proposed omnibus guidance covers a wide array of 340B Program topics, including definitions of eligible "patient" and eligible "covered outpatient drugs" as well as guidance pertaining to the group purchasing organization (GPO) prohibition and Medicaid managed care prescriptions. (For further discussion, see here.) It is important to note, however, that the proposed omnibus guidance has been issued pursuant to a more formal notice and comment process and as such may be accorded more judicial deference than the Orphan Drug Guidance. The Court decision does, however, bring to the forefront the ability of affected 340B Program participants (covered entities and drug manufacturers alike) to challenge portions of the proposed omnibus guidance with which such participants disagree. 

Since the Court issued its decision, HRSA has removed the Orphan Drug Guidance from its website. At this time, it is unclear as to how HRSA will approach compliance with the orphan drug exclusion.

Federal Court Rejects HHS Interpretation of 340B Program's Orphan Drug Rule

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.